Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:GILD
CUSIP: 37555810
Web: www.gilead.com

Capitalization:

Market Cap: $108.74 billion
Outstanding Shares: 1,305,926,000

Average Prices:

50 Day Moving Avg: $77.54
200 Day Moving Avg: $70.38
52 Week Range: $63.76 - $86.27

P/E:

Trailing P/E Ratio: 9.04
Foreward P/E Ratio: 11.09
P/E Growth: -1.15

Sales & Book Value:

Annual Revenue: $28.47 billion
Price / Sales: 3.82
Book Value: $17.36 per share
Price / Book: 4.80

Dividend:

Annual Dividend: $2.08
Dividend Yield: 2.5%

Profitability:

EBIDTA: $17.97 billion
Net Margins: 42.90%
Return on Equity: 66.07%
Return on Assets: 23.03%

Debt:

Debt-to-Equity Ratio: 1.16%
Current Ratio: 3.37%
Quick Ratio: 3.20%

Misc:

Average Volume: 10.17 million shs.
Beta: 1.19
Short Ratio: 2.17

Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Wednesday, July 26th. Investors of record on Friday, September 15th will be paid a dividend of $0.52 per share on Thursday, September 28th. This represents a $2.08 annualized dividend and a yield of 2.50%. The ex-dividend date is Thursday, September 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Wednesday, July, 26th. The company reported $2.56 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analysts' expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences's revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.08 EPS. View Gilead Sciences' Earnings History.

When will Gilead Sciences make its next earnings announcement?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Gilead Sciences.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

26 brokerages have issued twelve-month target prices for Gilead Sciences' shares. Their predictions range from $68.00 to $100.00. On average, they anticipate Gilead Sciences' share price to reach $84.62 in the next twelve months. View Analyst Ratings for Gilead Sciences.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. According to Zacks Investment Research, "Gilead is all set to acquire Kite Pharma and enter the CAR T therapy space which represents immense potential at this juncture and a potential approval of lead candidate axi-cell will be a significant boost for Gilead’s prospects which has dampened of late. We note that an acquisition announcement was on the cards as Gilead had a strong cash balance and the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure made the company look for strategic alternatives. Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise is under pressure because of competition and pricing issues. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU. Shares of the company have outperformed the industry so far in 2017." (9/11/2017)
2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene Corporation (CELG), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), AveXis (AVXS), Sarepta Therapeutics (SRPT) and GW Pharmaceuticals PLC (GWPH).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

John C. Martin Ph.D., Executive Chairman of the Board
John F. Milligan Ph.D., Chief Executive Officer, Director
Robin L. Washington, Chief Financial Officer, Executive Vice President
Kevin B. Young, Chief Operating Officer
Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
James R. Meyers, Executive Vice President - Worldwide Commercial Operations
John F. Cogan Jr. Ph.D., Lead Independent Director
Kelly A. Kramer, Independent Director
Kevin E. Lofton, Independent Director

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.03%), Vanguard Group Inc. (7.11%), State Street Corp (4.45%), Bank of New York Mellon Corp (2.36%), FMR LLC (1.76%) and Capital Research Global Investors (1.40%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Capital Research Global Investors, Los Angeles Capital Management & Equity Research Inc., State Street Corp, American Century Companies Inc., AJO LP, Thrivent Financial For Lutherans and Nordea Investment Management AB. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, James R Meyers, John C Martin, John Francis Cogan, John W Madigan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., The Manufacturers Life Insurance Company , BlackRock Inc., Pioneer Investment Management Inc., Janus Henderson Group PLC, Neuberger Berman Group LLC and Harbour Capital Advisors LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $83.27.

MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:		3.7 out of 5 ( )
Outperform Votes:		1,583 (Vote Outperform)
Underperform Votes:		557 (Vote Underperform)
Total Votes:		2,140

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	9 Hold Ratings, 17 Buy Ratings
Consensus Rating:	Buy (Score: 2.65)
Consensus Price Target:	$84.62 (1.62% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/20/2017	Leerink Swann	Reiterated Rating	Market Perform	$82.00 -> $87.00	Medium
9/14/2017	Royal Bank Of Canada	Initiated Coverage	Outperform -> Outperform	$94.00	Low
9/6/2017	Berenberg Bank	Reiterated Rating	Buy	$86.00 -> $96.00	Low
9/6/2017	Wells Fargo & Co	Boost Price Target	Market Perform	$73.00 -> $81.00	Low
8/31/2017	Cowen and Company	Reiterated Rating	Outperform	$90.00	Medium
8/31/2017	Deutsche Bank AG	Reiterated Rating	Buy	$81.00	Medium
8/31/2017	William Blair	Reiterated Rating	Outperform -> Outperform	$87.00	Low
8/31/2017	Argus	Upgrade	Hold -> Buy	$100.00	High
8/28/2017	Needham & Company LLC	Reiterated Rating	Hold		Low
8/29/2017	Robert W. Baird	Reiterated Rating	Outperform	$87.00	Low
8/29/2017	Credit Suisse Group	Reiterated Rating	Outperform	$79.00 -> $85.00	Medium
8/28/2017	Maxim Group	Reiterated Rating	Hold		High
7/27/2017	BMO Capital Markets	Reiterated Rating	Outperform	$72.00 -> $82.00	Medium
7/27/2017	Jefferies Group LLC	Reiterated Rating	Hold	$83.00	Medium
7/27/2017	J P Morgan Chase & Co	Set Price Target	Overweight	$80.00 -> $85.00	Medium
7/26/2017	Redburn Partners	Initiated Coverage	Buy		Medium
7/11/2017	Morgan Stanley	Reiterated Rating	Equal Weight		Low
5/3/2017	Gabelli	Reiterated Rating	Buy	$85.00	Medium
5/3/2017	Barclays PLC	Reiterated Rating	Overweight	$85.00	Medium
5/3/2017	Stifel Nicolaus	Reiterated Rating	Buy	$87.00	Medium
4/21/2017	Piper Jaffray Companies	Reiterated Rating	Buy		Low
3/13/2017	Bank of America Corporation	Reiterated Rating	Neutral	$76.00 -> $68.19	Low
3/13/2017	Goldman Sachs Group, Inc. (The)	Reiterated Rating	Neutral	$70.00 -> $68.00	Low
3/1/2017	Mizuho	Lower Price Target	Buy	$88.00 -> $77.00	N/A
2/8/2017	Citigroup Inc.	Downgrade	Buy -> Neutral	$87.00 -> $76.00	N/A
10/15/2016	Evercore ISI	Set Price Target	Buy	$90.00	N/A
7/27/2016	S&P Equity Research	Reiterated Rating	Strong-Buy		N/A
5/4/2016	Oppenheimer Holdings, Inc.	Reiterated Rating	Buy	$120.00 -> $116.00	N/A
2/3/2016	Standpoint Research	Initiated Coverage	Buy	$110.00	N/A
12/18/2015	Atlantic Securities	Initiated Coverage	Neutral	$111.00	N/A

(Data available from 9/25/2015 forward)

Earnings History for Gilead Sciences (NASDAQ:GILD)

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Earnings History by Quarter for Gilead Sciences (NASDAQ GILD)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/30/2017		$2.11					N/A
7/26/2017	Q2 2017	$2.11	$2.56	$6.35 billion	$7.14 billion	View	N/A
5/2/2017	Q1 2017	$2.18	$2.20	$6.66 billion	$6.51 billion	View	Listen
2/7/2017	Q416	$2.61	$2.70	$7.16 billion	$7.30 billion	View	Listen
11/1/2016	Q316	$2.87	$2.75	$7.47 billion	$7.40 billion	View	Listen
7/25/2016	Q216	$3.02	$3.08	$7.80 billion	$7.78 billion	View	Listen
4/28/2016	Q116	$3.13	$3.03	$8.08 billion	$7.80 billion	View	Listen
2/2/2016	Q415	$3.00	$3.32	$8.11 billion	$8.51 billion	View	Listen
10/27/2015	Q315	$2.87	$3.22	$7.84 billion	$8.30 billion	View	Listen
7/28/2015	Q215	$2.83	$3.15	$7.60 billion	$8.22 billion	View	Listen
4/30/2015	Q115	$2.78	$2.94	$6.81 billion	$7.59 billion	View	Listen
2/3/2015	Q414	$2.27	$2.43	$6.68 million	$7.31 billion	View	Listen
10/28/2014	Q314	$1.92	$1.84	$5.99 billion	$6.04 billion	View	Listen
7/23/2014	Q214	$1.61	$2.36	$5.68 billion	$6.53 billion	View	Listen
4/22/2014	Q114	$0.75	$1.48	$3.80 billion	$5.00 billion	View	Listen
2/4/2014	Q413	$0.50	$0.55	$2.85 billion	$3.04 billion	View	Listen
10/29/2013	Q313	$0.48	$0.52	$2.72 billion	$2.78 billion	View	Listen
7/25/2013	Q2 2013	$0.50	$0.50	$2.66 billion	$2.77 billion	View	Listen
5/2/2013	Q1 2013	$0.50	$0.48	$2.57 billion	$2.53 billion	View	Listen
2/4/2013	Q4 2012	$0.48	$0.50	$2.43 billion	$2.59 billion	View	Listen
10/23/2012		$0.94	$1.00			View	N/A
7/26/2012		$0.95	$0.99			View	N/A
4/26/2012		$0.94	$0.91			View	N/A
2/2/2012		$1.04	$0.97			View	N/A
10/27/2011		$1.01	$1.02			View	N/A
4/20/2011		$0.97	$0.87			View	N/A
1/25/2011		$0.95	$0.95			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)

2017 EPS Consensus Estimate: $8.25

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	$2.09	$2.42	$2.23
Q2 2017	3	$2.01	$2.29	$2.15
Q3 2017	3	$1.88	$2.26	$2.01
Q4 2017	3	$1.76	$2.03	$1.86

(Data provided by Zacks Investment Research)

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)

Next Dividend:	9/28/2017
Annual Dividend:	$2.08
Dividend Yield:	2.50%
Payout Ratio:	22.58% (Trailing 12 Months of Earnings) 23.69% (Based on This Year's Estimates) 27.70% (Based on Next Year's Estimates)

Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ GILD)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/26/2017	quarterly	$0.52	2.78%	9/14/2017	9/15/2017	9/28/2017
5/2/2017	quarterly	$0.52	3.09%	6/14/2017	6/16/2017	6/29/2017
2/7/2017	quarterly	$0.52	3.11%	3/14/2017	3/16/2017	3/30/2017
11/1/2016	quarterly	$0.47	2.59%	12/13/2016	12/15/2016	12/29/2016
7/25/2016	quarterly	$0.47	2.32%	9/14/2016	9/16/2016	9/29/2016
4/28/2016	quarterly	$0.47	2.13%	6/14/2016	6/16/2016	6/29/2016
2/2/2016	quarterly	$0.43	1.99%	3/14/2016	3/16/2016	3/30/2016
10/27/2015	quarterly	$0.43	1.59%	12/14/2015	12/16/2015	12/30/2015
7/28/2015	quarterly	$0.43	1.49%	9/14/2015	9/16/2015	9/29/2015
4/30/2015	quarterly	$0.43		6/12/2015	6/16/2015	6/29/2015

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 73.97%

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/7/2017	Robin L Washington	CFO	Sell	51,820	$85.00	$4,404,700.00
9/1/2017	Gregg H Alton	EVP	Sell	25,000	$83.05	$2,076,250.00
9/1/2017	John C Martin	Insider	Sell	73,333	$83.11	$6,094,705.63
8/31/2017	James R Meyers	EVP	Sell	60,000	$83.19	$4,991,400.00
8/30/2017	Gregg H Alton	EVP	Sell	50,000	$79.00	$3,950,000.00
8/1/2017	Gregg H Alton	EVP	Sell	15,000	$75.88	$1,138,200.00
8/1/2017	John C Martin	Insider	Sell	73,333	$75.86	$5,563,041.38
7/21/2017	Gregg H Alton	EVP	Sell	40,000	$74.00	$2,960,000.00
7/3/2017	Gregg H Alton	EVP	Sell	5,000	$71.06	$355,300.00
7/3/2017	John C Martin	Insider	Sell	73,333	$71.00	$5,206,643.00
5/9/2017	John Francis Cogan	Director	Sell	9,943	$67.25	$668,666.75
4/3/2017	John C Martin	Insider	Sell	73,333	$67.18	$4,926,510.94
3/30/2017	Gregg H Alton	EVP	Sell	5,000	$67.48	$337,400.00
1/3/2017	John C Martin	Insider	Sell	73,337	$73.59	$5,396,869.83
11/18/2016	John W Madigan	Director	Sell	105,000	$74.86	$7,860,300.00
10/3/2016	John C Martin	Insider	Sell	100,000	$77.63	$7,763,000.00
9/22/2016	Gregg H Alton	EVP	Sell	5,000	$81.84	$409,200.00
9/6/2016	John F Milligan	Insider	Sell	70,000	$77.74	$5,441,800.00
9/1/2016	John C Martin	Insider	Sell	100,000	$77.48	$7,748,000.00
8/24/2016	Kevin E Lofton	Director	Sell	3,500	$81.97	$286,895.00
8/1/2016	John C Martin	Insider	Sell	100,000	$80.50	$8,050,000.00
8/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$79.81	$159,620.00
7/5/2016	John F Milligan	CEO	Sell	112,000	$84.33	$9,444,960.00
7/1/2016	John C Martin	Chairman	Sell	100,000	$84.73	$8,473,000.00
7/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$83.12	$166,240.00
6/6/2016	John F Milligan	CEO	Sell	112,000	$86.94	$9,737,280.00
6/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$87.02	$174,040.00
5/2/2016	John C Martin	Chairman	Sell	100,000	$87.82	$8,782,000.00
5/2/2016	John F Milligan	CEO	Sell	112,000	$87.71	$9,823,520.00
5/2/2016	Paul Rutherford Carter	EVP	Sell	2,000	$88.72	$177,440.00
4/19/2016	Gregg H Alton	EVP	Sell	40,000	$100.01	$4,000,400.00
4/4/2016	John F Milligan	CEO	Sell	112,000	$94.59	$10,594,080.00
4/1/2016	John C Martin	Chairman	Sell	100,000	$93.24	$9,324,000.00
4/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$91.34	$182,680.00
3/14/2016	Gregg H Alton	EVP	Sell	5,000	$90.00	$450,000.00
2/26/2016	Gayle E Wilson	Director	Sell	6,650	$90.61	$602,556.50
2/1/2016	John C. Martin	CEO	Sell	100,000	$83.42	$8,342,000.00
2/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$82.32	$164,640.00
1/4/2016	John C. Martin	CEO	Sell	100,000	$97.68	$9,768,000.00
1/4/2016	Paul Rutherford Carter	EVP	Sell	2,000	$99.20	$198,400.00
12/15/2015	Norbert W. Bischofberger	EVP	Sell	70,000	$102.41	$7,168,700.00
12/7/2015	John F. Milligan	COO	Sell	100,000	$103.18	$10,318,000.00
11/24/2015	John Francis Cogan	Director	Sell	15,000	$105.95	$1,589,250.00
11/2/2015	Gregg H. Alton	EVP	Sell	12,000	$109.38	$1,312,560.00
11/2/2015	John C. Martin	CEO	Sell	150,000	$109.42	$16,413,000.00
11/2/2015	Robin L Washington	CFO	Sell	6,250	$109.46	$684,125.00
10/27/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00
10/26/2015	Gregg H. Alton	EVP	Sell	5,000	$110.00	$550,000.00
10/26/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00
10/15/2015	Norbert W. Bischofberger	EVP	Sell	70,000	$100.05	$7,003,500.00
10/7/2015	John F. Milligan	COO	Sell	100,000	$99.22	$9,922,000.00
10/5/2015	Gregg H. Alton	EVP	Sell	5,000	$100.00	$500,000.00
10/1/2015	John C. Martin	CEO	Sell	150,000	$97.48	$14,622,000.00
10/1/2015	Paul Rutherford Carter	EVP	Sell	2,000	$98.59	$197,180.00
9/15/2015	Gregg H. Alton	EVP	Sell	5,000	$110.00	$550,000.00
9/15/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00
9/8/2015	John F. Milligan	COO	Sell	100,000	$103.39	$10,339,000.00
9/2/2015	Robin L Washington	CFO	Sell	6,250	$102.20	$638,750.00
9/1/2015	John C. Martin	CEO	Sell	150,000	$102.73	$15,409,500.00
8/28/2015	Gayle E. Wilson	Director	Sell	21,000	$106.96	$2,246,160.00
8/25/2015	John C. Martin	CEO	Sell	133,213	$105.17	$14,010,011.21
8/17/2015	Norbert W Bischofberger	EVP	Sell	70,000	$116.16	$8,131,200.00
7/7/2015	John F Milligan	COO	Sell	100,000	$114.44	$11,444,000.00
6/26/2015	John Francis Cogan	Director	Sell	27,000	$120.13	$3,243,510.00
6/18/2015	Paul Rutherford Carter	EVP	Sell	10,000	$120.00	$1,200,000.00
6/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$117.67	$8,236,900.00
6/8/2015	John F Milligan	COO	Sell	100,000	$114.05	$11,405,000.00
6/1/2015	Gregg H Alton	EVP	Sell	17,000	$113.64	$1,931,880.00
6/1/2015	John C Martin	CEO	Sell	150,000	$113.95	$17,092,500.00
4/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$103.84	$7,268,800.00
4/8/2015	Paul Rutherford Carter	EVP	Sell	1,000	$100.00	$100,000.00
4/1/2015	Gregg H Alton	EVP	Sell	7,000	$96.53	$675,710.00
4/1/2015	John C Martin	CEO	Sell	150,000	$96.74	$14,511,000.00
3/2/2015	John C Martin	CEO	Sell	150,000	$103.51	$15,526,500.00
3/2/2015	Paul Rutherford Carter	EVP	Sell	2,000	$104.18	$208,360.00
3/2/2015	Richard James Whitley	Director	Sell	5,000	$103.43	$517,150.00
2/6/2015	Olsen Per Wold	Director	Buy	10,000	$99.92	$999,200.00
2/2/2015	Gregg H Alton	EVP	Sell	12,000	$105.73	$1,268,760.00
2/2/2015	John C Martin	CEO	Sell	150,000	$105.43	$15,814,500.00
2/2/2015	Robin L Washington	CFO	Sell	33,192	$105.38	$3,497,772.96
1/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$98.47	$6,892,900.00
1/8/2015	Gregg H Alton	EVP	Sell	5,000	$100.89	$504,450.00
1/5/2015	John C Martin	CEO	Sell	150,000	$95.12	$14,268,000.00
1/2/2015	Gregg H Alton	EVP	Sell	7,000	$95.17	$666,190.00
1/2/2015	Richard James Whitley	Director	Sell	5,000	$95.22	$476,100.00
12/22/2014	John Francis Cogan	Director	Sell	26,000	$95.03	$2,470,780.00
12/8/2014	John F Milligan	COO	Sell	146,823	$106.26	$15,601,411.98
12/1/2014	John C Martin	CEO	Sell	140,633	$100.72	$14,164,555.76
12/1/2014	Paul Rutherford Carter	EVP	Sell	2,000	$100.02	$200,040.00
11/3/2014	John C Martin	CEO	Sell	140,625	$110.40	$15,525,000.00
11/3/2014	Richard James Whitley	Director	Sell	5,000	$112.02	$560,100.00
11/3/2014	Robin L Washington	CFO	Sell	33,192	$110.26	$3,659,749.92
10/24/2014	Paul Rutherford Carter	EVP	Sell	2,000	$110.00	$220,000.00
10/7/2014	John F Milligan	COO	Sell	146,895	$104.60	$15,365,217.00
10/1/2014	John C Martin	CEO	Sell	140,625	$105.91	$14,893,593.75
10/1/2014	Paul Rutherford Carter	EVP	Sell	2,000	$106.39	$212,780.00
10/1/2014	Richard James Whitley	Director	Sell	5,000	$106.99	$534,950.00
9/26/2014	Paul Rutherford Carter	EVP	Sell	2,000	$107.47	$214,940.00
9/22/2014	John Francis Cogan	Director	Sell	5,000	$106.60	$533,000.00
9/8/2014	John F Milligan	COO	Sell	146,895	$105.99	$15,569,401.05
9/2/2014	Gregg H Alton	EVP	Sell	33,000	$108.58	$3,583,140.00
9/2/2014	John C Martin	CEO	Sell	140,625	$108.64	$15,277,500.00
8/26/2014	Paul Rutherford Carter	EVP	Sell	10,000	$106.16	$1,061,600.00
8/25/2014	Robin L Washington	CFO	Sell	4,304	$105.87	$455,664.48
8/21/2014	John Francis Cogan	Director	Sell	5,000	$101.09	$505,450.00
8/14/2014	Robin L Washington	CFO	Sell	33,556	$95.56	$3,206,611.36
8/1/2014	Gregg H Alton	EVP	Sell	33,000	$91.62	$3,023,460.00
8/1/2014	John C Martin	CEO	Sell	140,625	$91.53	$12,871,406.25
8/1/2014	Richard James Whitley	Director	Sell	5,000	$91.00	$455,000.00
8/1/2014	Robin L Washington	CFO	Sell	30,600	$91.48	$2,799,288.00
7/28/2014	Nicholas G Moore	Director	Sell	45,000	$90.56	$4,075,200.00
7/21/2014	John Francis Cogan	Director	Sell	5,000	$89.67	$448,350.00
7/8/2014	Paul Rutherford Carter	EVP	Sell	16,728	$86.45	$1,446,135.60
7/1/2014	Gregg H Alton	EVP	Sell	33,000	$84.12	$2,775,960.00
7/1/2014	John C Martin	CEO	Sell	140,625	$84.84	$11,930,625.00
7/1/2014	Richard James Whitley	Director	Sell	5,000	$83.65	$418,250.00
6/30/2014	Robin L Washington	CFO	Sell	10,400	$83.98	$873,392.00
6/23/2014	John Francis Cogan	Director	Sell	5,000	$81.82	$409,100.00
6/16/2014	Norbert W Bischofberger	EVP	Sell	90,000	$80.90	$7,281,000.00
6/9/2014	Paul Rutherford Carter	EVP	Sell	16,728	$79.43	$1,328,705.04
6/4/2014	Robin L Washington	CFO	Sell	6,426	$82.52	$530,273.52
6/2/2014	Gregg H Alton	EVP	Sell	33,000	$81.35	$2,684,550.00
6/2/2014	Richard James Whitley	Director	Sell	5,000	$80.95	$404,750.00
5/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$80.65	$7,258,500.00
5/6/2014	Robin Washington	CFO	Sell	3,000	$79.91	$239,730.00
5/1/2014	Gregg Alton	EVP	Sell	13,000	$79.08	$1,028,040.00
5/1/2014	John Martin	CEO	Sell	140,625	$79.02	$11,112,187.50
5/1/2014	Richard James Whitley	Director	Sell	5,000	$78.63	$393,150.00
5/1/2014	Robin Washington	CFO	Sell	27,600	$79.16	$2,184,816.00
4/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$67.03	$6,032,700.00
4/8/2014	John Francis Cogan	Director	Sell	5,000	$70.55	$352,750.00
4/8/2014	Paul Rutherford Carter	EVP	Sell	16,728	$70.53	$1,179,825.84
4/1/2014	Gregg Alton	EVP	Sell	13,000	$73.20	$951,600.00
4/1/2014	John Martin	CEO	Sell	140,625	$73.26	$10,302,187.50
3/14/2014	John Francis Cogan	Director	Sell	14,000	$76.44	$1,070,160.00
3/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$75.89	$6,830,100.00
3/10/2014	Paul Rutherford Carter	EVP	Sell	16,728	$79.32	$1,326,864.96
3/3/2014	Gregg Alton	EVP	Sell	33,000	$81.84	$2,700,720.00
3/3/2014	John Martin	CEO	Sell	140,625	$81.74	$11,494,687.50
2/26/2014	Nicholas Moore	Director	Sell	20,000	$84.05	$1,681,000.00
2/19/2014	Nicholas Moore	Director	Sell	19,068	$83.12	$1,584,932.16
1/23/2014	Kevin Young	EVP	Sell	100,000	$81.44	$8,144,000.00
1/21/2014	Gregg Alton	EVP	Sell	120,000	$80.00	$9,600,000.00
1/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$74.23	$6,680,700.00
10/23/2013	Kevin Young	EVP	Sell	75,000	$68.56	$5,142,000.00
10/14/2013	Norbert Bischofberger	EVP	Sell	90,000	$62.54	$5,628,600.00
9/23/2013	Kevin Young	EVP	Sell	100,000	$62.88	$6,288,000.00
9/16/2013	Norbert Bischofberger	EVP	Sell	90,000	$63.11	$5,679,900.00
9/3/2013	Gregg Alton	EVP	Sell	30,000	$60.99	$1,829,700.00
9/3/2013	John Martin	CEO	Sell	282,242	$60.97	$17,208,294.74
8/30/2013	Nicholas Moore	Director	Sell	151,720	$60.42	$9,166,922.40
8/14/2013	Norbert Bischofberger	EVP	Sell	90,000	$58.77	$5,289,300.00
8/1/2013	Gregg H Alton	EVP	Sell	30,000	$61.49	$1,844,700.00
8/1/2013	John C Martin	CEO	Sell	282,242	$61.61	$17,388,929.62
7/30/2013	John W Madigan	Director	Sell	249,000	$61.97	$15,430,530.00
7/15/2013	Norbert W Bischofberger	EVP	Sell	90,000	$57.33	$5,159,700.00
7/2/2013	John Francis Cogan	Director	Sell	17,000	$51.66	$878,220.00
7/1/2013	Gregg H Alton	EVP	Sell	30,000	$52.09	$1,562,700.00
7/1/2013	John C Martin	CEO	Sell	282,242	$52.00	$14,676,584.00
7/1/2013	Robin L Washington	CFO	Sell	45,600	$52.01	$2,371,656.00
6/7/2013	John Francis Cogan	Director	Sell	110,000	$52.15	$5,736,500.00
6/3/2013	Gregg H Alton	EVP	Sell	30,000	$52.77	$1,583,100.00
6/3/2013	John C Martin	CEO	Sell	282,242	$52.84	$14,913,667.28
2/28/2013	Olsen Per Wold	Director	Buy	10,000	$43.05	$430,500.00
12/3/2012	Gregg H Alton	EVP	Sell	44,000	$75.10	$3,304,400.00
12/3/2012	John C Martin	CEO	Sell	291,000	$75.01	$21,827,910.00
11/12/2012	Robin L Washington	CFO	Sell	55,950	$73.11	$4,090,504.50
10/3/2012	John F Milligan	COO	Sell	140,000	$69.85	$9,779,000.00
10/2/2012	Robin L Washington	CFO	Sell	29,500	$68.62	$2,024,290.00
9/4/2012	Gregg H Alton	EVP	Sell	44,000	$57.50	$2,530,000.00

(Data available from 1/1/2013 forward)

Headline Trends for Gilead Sciences (NASDAQ:GILD) Latest Headlines for Gilead Sciences (NASDAQ:GILD)

Source:

Date	Headline
	Gilead Sciences, Inc. (GILD) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - September 23 at 12:40 PM
	Why We Bought Gilead This Week - Seeking Alpha seekingalpha.com - September 23 at 12:36 AM
	Gilead's (GILD) Epclusa Receives Label Expansion in Canada finance.yahoo.com - September 22 at 7:36 PM
	Gilead's (GILD) Epclusa Receives Label Expansion in Canada finance.yahoo.com - September 22 at 7:36 PM
	Gilead: Canada OKs Updated Labeling Of EPCLUSA For HCV/HIV Co-infected Patients www.rttnews.com - September 22 at 2:32 PM
	Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV finance.yahoo.com - September 22 at 2:32 PM
	Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion? www.fool.com - September 22 at 10:56 AM
	Should Value Investors Consider Gilead Sciences (GILD) Stock? - Yahoo Finance finance.yahoo.com - September 20 at 3:48 PM
	Why Gilead May Regain Growth Stock Status - Seeking Alpha seekingalpha.com - September 20 at 3:48 PM
	Gilead Sciences, Inc. (GILD) Earns Market Perform Rating from Leerink Swann www.americanbankingnews.com - September 20 at 2:38 PM
	Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors finance.yahoo.com - September 19 at 7:03 PM
	Taking On Exposure to Innovative Biotechnology Stocks finance.yahoo.com - September 19 at 7:03 PM
	Should Value Investors Consider Gilead Sciences (GILD) Stock? finance.yahoo.com - September 19 at 7:03 PM
	Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors www.fool.com - September 19 at 6:55 AM
	The IBB Biotechnology ETF: The Drugs You Need? finance.yahoo.com - September 18 at 6:36 PM
	Benefitting from IBB’s Lower Expense Ratio finance.yahoo.com - September 18 at 6:36 PM
	After Gilead Sciences, More Biotech M&A? finance.yahoo.com - September 15 at 7:41 PM
	3 Reasons Why Gilead Sciences Stock Is a Buy Now www.fool.com - September 15 at 8:16 AM
	Is It Premature to Celebrate Gilead Sciences, Inc.’s (GILD) Kite Pharma Momentum? Jefferies Looks Beyond the Recent Bull Rally finance.yahoo.com - September 15 at 12:46 AM
	Gilead Sciences prices $3B in debt for Kite Pharma deal seekingalpha.com - September 14 at 7:58 PM
	Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock finance.yahoo.com - September 14 at 7:43 PM
	Gilead Sciences, Inc. -- Moody's assigns A3 to Gilead's new sr. notes; stable outlook finance.yahoo.com - September 14 at 7:43 PM
	ETFs with exposure to Gilead Sciences, Inc. : September 14, 2017 finance.yahoo.com - September 14 at 7:43 PM
	Gilead Prices $3 Billion of Senior Unsecured Notes finance.yahoo.com - September 14 at 7:43 PM
	Royal Bank Of Canada Begins Coverage on Gilead Sciences, Inc. (GILD) www.americanbankingnews.com - September 14 at 5:26 PM
	Must-Know Recent Developments for Gilead finance.yahoo.com - September 14 at 1:59 AM
	Gilead: Too Early for Kite Credit? finance.yahoo.com - September 14 at 1:59 AM
	Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 finance.yahoo.com - September 14 at 1:59 AM
	Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals) finance.yahoo.com - September 14 at 1:59 AM
	Gilead Sciences, Inc. (GILD) Downgraded by ValuEngine www.americanbankingnews.com - September 14 at 12:56 AM
	Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals) www.fool.com - September 13 at 3:59 PM
	Ex-Dividend Reminder: Gilead Sciences, Hill-Rom Holdings and Owens & Minor www.nasdaq.com - September 12 at 7:54 PM
	How Gilead’s HCV Drugs Portfolio Performed in 2Q17 finance.yahoo.com - September 12 at 7:54 PM
	How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17? finance.yahoo.com - September 12 at 7:54 PM
	How Gilead’s Other Products Performed in 2Q17 finance.yahoo.com - September 12 at 7:54 PM
	3 Stocks for Future Millionaires www.fool.com - September 12 at 8:18 AM
	Cowen Shares Key Insights on Gilead Sciences, Inc. (GILD) Following Management Meetings finance.yahoo.com - September 12 at 12:35 AM
	How Did Gilead’s Revenue Trend in 2Q17? finance.yahoo.com - September 12 at 12:35 AM
	How Gilead’s HIV and HBV Portfolios Performed in 2Q17 finance.yahoo.com - September 12 at 12:35 AM
	Insider Selling: Gilead Sciences, Inc. (GILD) CFO Sells 51,820 Shares of Stock www.americanbankingnews.com - September 11 at 10:20 PM
	Gilead Sciences, Inc. (GILD) Upgraded to "B-" by TheStreet www.americanbankingnews.com - September 11 at 7:02 PM
	5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition www.fool.com - September 11 at 4:17 PM
	Gilead Sciences, Inc. (GILD) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - September 11 at 10:10 AM
	Head to Head Comparison: Gilead Sciences (GILD) and Vascular Biogenics (VBLT) www.americanbankingnews.com - September 10 at 8:52 AM
	GILD Crosses Above Average Analyst Target - Nasdaq www.nasdaq.com - September 9 at 11:37 PM
	Upgrade Confirms Gilead's Price Strength finance.yahoo.com - September 8 at 7:34 PM
	Gilead Sciences, Inc. (GILD) Upgraded to "Strong-Buy" at ValuEngine www.americanbankingnews.com - September 8 at 12:36 AM
	Alternative Perspectives On The Biotech M&A Environment finance.yahoo.com - September 7 at 7:16 PM
	The Trump White House Gave These Mutual Funds a Big Boost finance.yahoo.com - September 7 at 7:16 PM
	Unusual activity in a biotech and a travel stock finance.yahoo.com - September 7 at 7:16 PM